The Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
McMaster University, Hamilton, ON, Canada.
Curr Cardiol Rep. 2023 Sep;25(9):941-958. doi: 10.1007/s11886-023-01916-4. Epub 2023 Jul 27.
Bruton's tyrosine kinase inhibitors (BTKis) have changed the treatment and prognosis of several B-cell malignancies. However, since the approval of the first BTKi, ibrutinib, reports of cardiovascular adverse events especially atrial fibrillation have arisen. In this review, we discuss the cardiovascular side effects of BTKis and the management of these toxicities in clinical practice.
BTKIs increase the risks of atrial fibrillation, bleeding, hypertension, heart failure, and potentially ventricular arrhythmia. Newer second and third-generation BTKis appear to have a lower risk of cardiovascular adverse events; however, long-term follow-up data are not available for these new BTKis. BTKis are an effective treatment for some B-cell malignancies; however, they can cause cardiovascular side effects. The best preventive strategies to minimize cardiovascular complications remain undefined. Currently, a practical approach for managing patients receiving BTKis includes the management of cardiovascular risk factors and side effects of BTKis to prevent interruption of cancer treatment.
布鲁顿酪氨酸激酶抑制剂（BTKi）改变了多种 B 细胞恶性肿瘤的治疗和预后。然而，自首个 BTKi，伊布替尼获批以来，有关心血管不良事件（特别是心房颤动）的报告不断出现。在本综述中，我们讨论了 BTKi 的心血管副作用以及在临床实践中这些毒性的管理。
BTKi 增加了心房颤动、出血、高血压、心力衰竭和潜在的室性心律失常的风险。新型第二代和第三代 BTKi 似乎具有较低的心血管不良事件风险；然而，这些新型 BTKi 尚无长期随访数据。BTKi 是某些 B 细胞恶性肿瘤的有效治疗方法；然而，它们会引起心血管副作用。最大限度减少心血管并发症的最佳预防策略仍未确定。目前，管理接受 BTKi 治疗的患者的实用方法包括管理心血管危险因素和 BTKi 的副作用，以防止癌症治疗中断。
